

In this open-label, randomized trial, the RSV vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine among adults 60 years of age or older.
Geriatrics/Aging
|11th Mar, 2026
|The New England Journal of Medicine
Geriatrics/Aging
|11th Mar, 2026
|The New England Journal of Medicine
Geriatrics/Aging
|11th Mar, 2026
|The New England Journal of Medicine
Geriatrics/Aging
|11th Mar, 2026
|The New England Journal of Medicine
Geriatrics/Aging
|11th Mar, 2026
|The New England Journal of Medicine
Geriatrics/Aging
|11th Mar, 2026
|The New England Journal of Medicine
Geriatrics/Aging
|11th Mar, 2026
|The New England Journal of Medicine